Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.

In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system. MS disrupts the flow of information between the ...

Specialists in multiple sclerosis will gather in San Diego for ACTRIMS Forum 2026, Feb. 5-7, where the theme will be “MS at a ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on multiple sclerosis, has published groundbreaking new research ...

Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...